2017
DOI: 10.1007/s11926-017-0633-0
|View full text |Cite
|
Sign up to set email alerts
|

Therapies of Early, Advanced, and Late Onset Forms of Axial Spondyloarthritis, and the Need for Treat to Target Strategies

Abstract: Efficacy of TNF inhibitors has been assessed in randomized controlled trials in axSpA, which included patients who had non-radiographic axSpA according to the ASAS classification criteria. The role of IL17/23 pathway as a therapeutic target in ankylosing spondylitis (AS) has been the focus of phase III studies of secukinumab (named MEASURE 1 and MEASURE 2) and a proof-of-concept study of ustekinumab. Potential efficacy of novel small molecules such as apremilast and tofacitinib has been explored in recent phas… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
8
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 11 publications
(8 citation statements)
references
References 95 publications
0
8
0
Order By: Relevance
“…Indeed, the determination of the MMPs is fast and painless and does not need to use expensive imaging systems. Finally, the study results could help in decision making, facilitating the adequate selection of treatment approaches or the identification of clinical effects for spinal pain patients [76][77][78].…”
Section: Strengths and Limitationsmentioning
confidence: 99%
“…Indeed, the determination of the MMPs is fast and painless and does not need to use expensive imaging systems. Finally, the study results could help in decision making, facilitating the adequate selection of treatment approaches or the identification of clinical effects for spinal pain patients [76][77][78].…”
Section: Strengths and Limitationsmentioning
confidence: 99%
“…More recently, a monoclonal antibody that inhibits interleukin‐17A (IL‐17A) was approved to treat adults with AS . Although these agents show efficacy in many patients with axial SpA, some patients do not respond adequately; thus, there is a need to target other mechanisms of action .…”
Section: Introductionmentioning
confidence: 99%
“…Within the last years, the same treatment strategy has been shown to reduce arthritis activity in patients with PsA compared to previous treatment regimes (12). In daily clinical practice, SpA is treated after the T2T recommendations (13), but this is mainly based on expert opinions, as there currently is no clinical evidence of T2T in SpA (14)(15)(16). However, these individualized strategies is used as expert assessment finds it very likely to improve patient outcomes and long-term quality of life (13).…”
Section: Inflammatory Conditions: Managementmentioning
confidence: 99%